Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12606000156583
Ethics application status
Approved
Date submitted
3/06/2001
Date registered
3/06/2001
Date last updated
2/05/2006
Type of registration
Retrospectively registered
Titles & IDs
Public title
Oral misoprostal for the induction of labour at term
Query!
Scientific title
Oral misoprostol versus vaginal prostaglandin E2 for the induction of labour at term (beyond 37 weeks gestation).
Query!
Secondary ID [1]
28
0
Perinatal Trials Registry: PTR361
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
MILO
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pregnancy at a gestational age of 37 weeks or more.
29
0
Query!
Condition category
Condition code
Reproductive Health and Childbirth
33
33
0
0
Query!
Childbirth and postnatal care
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Misoprostol group: oral misoprostol in solution (1mg/ml) 20 mls repeated two hourly to a maxmimum of 12 doses plus placebo vaginal gel treatment. Vaginal prostaglandin group: oral placebo (25mg pyradoxive) following dosing regimen described above plus prostaglandin vaginal gel
Query!
Intervention code [1]
1013
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
60
0
Caesarean section
Query!
Assessment method [1]
60
0
Query!
Timepoint [1]
60
0
Assessed during induction and labour
Query!
Primary outcome [2]
61
0
Women undelivered after 24 hours
Query!
Assessment method [2]
61
0
Query!
Timepoint [2]
61
0
Assessed during induction and labour
Query!
Primary outcome [3]
62
0
Uterine hyperstimulation with fetal heart rate abnormality
Query!
Assessment method [3]
62
0
Query!
Timepoint [3]
62
0
Assessed during induction and labour
Query!
Secondary outcome [1]
102
0
Admission to Neonatal Intensive Care Unit (NICU).
Query!
Assessment method [1]
102
0
Query!
Timepoint [1]
102
0
Query!
Secondary outcome [2]
103
0
Length of stay (neonatal).
Query!
Assessment method [2]
103
0
Query!
Timepoint [2]
103
0
Query!
Secondary outcome [3]
104
0
Maternal and neonatal morbidity
Query!
Assessment method [3]
104
0
Query!
Timepoint [3]
104
0
Measured up to six weeks postpartum.
Query!
Eligibility
Key inclusion criteria
Singleton pregnancy, at a gestational age of 37 weeks or more, planned induction of labour for defined obstetric and medical conditions - prolonged pregnancy, pre-eclampsia, hypertensive disoreders, antepartum haemorrhage (ecluding placenta praevia), oligohydramnios, IUGR, or abnormal glucose tolerance.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
Not stated
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Induction planned for non-defined conditions, active labour o, or a favourable cervix, contraindication to vaginal birth, previous uterine surgery, ruptured membranes, parity 5 or more, history of asthma, glaucoma or heart disease, suspected cephalo-pelvic disproportion, abnormal lie, breech presentation, fetal distress/non-reassuring fetal heart trace, multiple pregnancy, intrauterine infection, vasa praevia, placenta praevia, active herpes infection, maternal illness precluding induction of labour, and maternal renal or hepatic failure.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Identical appearing treatment packs
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated randomisation
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
30/03/2001
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
738
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
43
0
Hospital
Query!
Name [1]
43
0
Women's and Children's Hospital Research Foundation Project Grant
Query!
Address [1]
43
0
Query!
Country [1]
43
0
Australia
Query!
Primary sponsor type
University
Query!
Name
The Department of Obstetrics & Gynaecology, The University of Adelaide
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
37
0
None
Query!
Name [1]
37
0
Nil
Query!
Address [1]
37
0
Query!
Country [1]
37
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
327
0
Women's and Children's Hospital
Query!
Ethics committee address [1]
327
0
Query!
Ethics committee country [1]
327
0
Australia
Query!
Date submitted for ethics approval [1]
327
0
Query!
Approval date [1]
327
0
Query!
Ethics approval number [1]
327
0
Query!
Summary
Brief summary
This is a prospective randomised, double blind, placebo controlled trial comparing vaginal prostaglandins E2 gel with an oral synthetic prostaglandin E2 analogue (misoprostol) in the induction of labour at term. Both agents are thought to be equally effective in inducing labour. The main outcomes assessed in this study will be the rate of caesarean section, the number of women who remain undelivered after 24 hours, and uterine hyperstimulation with associated changes in the fetal heart rate. Women, caregivers and outcome assessors (MILO trial) are blinded. For the timing of induction component, it is not possible for women or caregivers to be blinded.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
36341
0
Query!
Address
36341
0
Query!
Country
36341
0
Query!
Phone
36341
0
Query!
Fax
36341
0
Query!
Email
36341
0
Query!
Contact person for public queries
Name
10202
0
Jacki Smith
Query!
Address
10202
0
The Discipline of Obstetrics and Gynaecology
The University of Adelaide
Women's and Children's Hospital (WCH)
72 King William Road
North Adelaide SA 5019
Query!
Country
10202
0
Australia
Query!
Phone
10202
0
+61 8 81617619
Query!
Fax
10202
0
+61 8 81617652
Query!
Email
10202
0
[email protected]
Query!
Contact person for scientific queries
Name
1130
0
Dr Jodie Dodd
Query!
Address
1130
0
Discipline of Obstetrics & Gynaecology, The University of Adelaide
Women's & Children's Hospital
72 King William Road, North Adelaide
SA 5019
Query!
Country
1130
0
Australia
Query!
Phone
1130
0
+61 8 81617619
Query!
Fax
1130
0
+61 8 81617652
Query!
Email
1130
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF